The effect of subclinical maternal thyroid dysfunction and autoimmunity on intrauterine growth restriction: A systematic review and meta-analysis

Medicine (United States)

Volumn 95, Issue 19, 2016, Pages

  Tong, Zhao ^a   Xiaowen, Zhang ^a   Baomin, Chen ^a   Aihua, Liu ^a   Yingying, Zhou ^a   Weiping, Teng ^a   Zhongyan, Shan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY; AUTOANTIBODY; THYROID MICROSOMAL ANTIBODIES;

AUTOIMMUNITY; DISEASE ASSOCIATION; FIRST TRIMESTER PREGNANCY; GENETIC HETEROGENEITY; HUMAN; HYPOTHYROXINEMIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; SYSTEMATIC REVIEW; THYROID DISEASE; ADULT; BLOOD; COMPLICATION; FEMALE; FETAL GROWTH RETARDATION; IMMUNOLOGY; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY OUTCOME; RISK FACTOR; THYROID GLAND;

ADULT; AUTOANTIBODIES; AUTOIMMUNITY; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PREGNANCY; PREGNANCY OUTCOME; RISK FACTORS; THYROID DISEASES; THYROID GLAND;

EID: 84969930746     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003677     Document Type: Review

References (41)

1. Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol. 2011;204:288-300.
2. Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr. 1967;71:159-163.
3. Franco B, Laura F, Sara N, Salvatore G. Thyroid function in small for gestational age newborns: A review. J Clin Res Pediatr Endocrinol. 2013;5(Suppl 1):2-7.
4. McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med. 1999;340:1234-1238.
5. Cianfarani S, Maiorana A, Geremia C, et al. Blood glucose concentrations are reduced in children born small for gestational age (SGA), and thyroid-stimulating hormone levels are increased in SGA with blunted postnatal catch-up growth. J Clin Endocrinol Metab. 2003;88:2699-2705.
6. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-67.
7. Kumru P, Erdogdu E, Arisoy R, et al. Effect of thyroid dysfunction and autoimmunity on pregnancy outcomes in low risk population. Arch Gynecol Obstet. 2014;291:1047-1054.
8. Sahu MT, Das V, Mittal S, et al. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. Arch Gynecol Obstet. 2010;281: 215-220.
9. Saki F, Dabbaghmanesh MH, Ghaemi SZ, et al. Thyroid function in pregnancy and its influences on maternal and fetal outcomes. Int J Endocrinol Metab. 2014;12:e19378.
10. Mannisto T, Vaarasmaki M, Pouta A, et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: A prospective population-based cohort study. J Clin Endocrinol Metab. 2009;94:772-779.
11. Su PY, Huang K, Hao JH, et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: A prospective population-based cohort study in China. J Clin Endocrinol Metab. 2011;96:3234-3241.
12. Chen LM, Du WJ, Dai J, et al. Effects of subclinical hypothyroidism on maternal and perinatal outcomes during pregnancy: A single-center cohort study of a Chinese population. PLoS One. 2014;9:e109364.
13. Breathnach FM, Donnelly J, Cooley SM, et al. Subclinical hypothyroidism as a risk factor for placental abruption: evidence from a lowrisk primigravid population. Aust N Z J Obstet Gynaecol. 2013;53: 553-560.
14. Chen L-M, Zhang Q, Si G-X, et al. Associations between thyroid autoantibody status and abnormal pregnancy outcomes in euthyroid women. Endocrine. 2014;48:924-928.
15. Wilson RE, Salihu HM, Groer MW, et al. Impact of maternal thyroperoxidase status on fetal body and brain size. J Thyroid Res. 2014;2014:1-8.
16. Abbassi-Ghanavati M, Casey BM, Spong CY, et al. Pregnancy outcomes in women with thyroid peroxidase antibodies. Obstetr Gynecol. 2010;116 (2 Pt 1):381-386.
17. Saki F, Dabbaghmanesh MH, Ghaemi SZ, et al. Thyroid autoimmunity in pregnancy and its influences on maternal and fetal outcome in Iran (a prospective study). Endocr Res. 2015;40:139-145.
18. Hamm MP, Cherry NM, Martin JW, et al. The impact of isolated maternal hypothyroxinemia on perinatal morbidity. J Obstet Gynaecol Can. 2009;31:1015-1021.
19. Ong GS, Hadlow NC, Brown SJ, et al. Does the thyroid-stimulating hormone measured concurrently with first trimester biochemical screening tests predict adverse pregnancy outcomes occurring after 20 weeks gestation? J Clin Endocrinol Metab. 2014;99:E2668-2672.
20. Barber KJ, Franklyn JA, McCabe CJ, et al. The in vitro effects of triiodothyronine on epidermal growth factor-induced trophoblast function. J Clin Endocrinol Metab. 2005;90:1655-1661.
21. LaFranchi SH, Haddow JE, Hollowell JG. Is thyroid inadequacy during gestation a risk factor for adverse pregnancy and developmental outcomes? Thyroid. 2005;15:60-71.
22. Chang DLF, Pearce EN. Screening for maternal thyroid dysfunction in pregnancy: A review of the clinical evidence and current guidelines. J Thyroid Res. 2013;2013:1-8.
23. Mannisto T, Mendola P, Reddy U, Laughon SK. Neonatal outcomes and birth weight in pregnancies complicated by maternal thyroid disease. Am J Epidemiol. 2013;178:731-740.
24. Millar LK, Wing DA, Leung AS, et al. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstetr Gynecol. 1994;84:946-949.
25. Mitsuda N, Tamaki H, Amino N, et al. Risk factors for developmental disorders in infants born to women with Graves disease. Obstetr Gynecol. 1992;80 (3 Pt 1):359-364.
26. Leon G, Murcia M, Rebagliato M, et al. Maternal thyroid dysfunction during gestation, preterm delivery, and birthweight. The Infancia y Medio Ambiente Cohort, Spain. Paediatr Perinat Epidemiol. 2015;29:113-122.
27. Mannisto T, Vaarasmaki M, Pouta A, et al. Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. J Clin Endocrinol Metab. 2010;95:1084-1094.
28. Nelson DB, Casey BM, McIntire DD, Cunningham FG. Subsequent pregnancy outcomes in women previously diagnosed with subclinical hypothyroidism. Am J Perinatol. 2014;31:77-84.
29. Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstetr Gynecol. 2005;105:239-245.
30. Casey BM, Dashe JS, Wells CE, et al. Subclinical hyperthyroidism and pregnancy outcomes. Obstetr Gynecol. 2006;107 (2 Pt 1):337-341.
31. Stagnaro-Green A, Pearce E. Thyroid disorders in pregnancy. Nat Rev Endocrinol. 2012;8:650-658.
32. Glinoer D, Soto MF, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991;73:421-427.
33. Glinoer D, Riahi M, Grun JP, Kinthaert J. Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. J Clin Endocrinol Metab. 1994;79:197-204.
34. Stagnaro-Green A, Roman SH, Cobin RH, et al. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA. 1990;264:1422-1425.
35. Stagnaro-Green A. Maternal thyroid disease and preterm delivery. J Clin Endocrinol Metab. 2009;94:21-25.
36. Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ. 2011;342:d2616.
37. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-1125.
38. Glinoer D. Management of hypo-and hyperthyroidism during pregnancy. Growth Horm IGF Res. 2003;13(Suppl A):S45-54.
39. Calvo RM, Jauniaux E, Gulbis B, et al. Fetal tissues are exposed to biologically relevant free thyroxine concentrations during early phases of development. J Clin Endocrinol Metab. 2002;87:1768-1777.
40. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for predicting intrauterine growth restriction: A systematic review and meta-analysis. BJOG. 2013;120:681-694.
41. Benhadi N, Wiersinga WM, Reitsma JB, et al. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol. 2009;160:985-991.